Get an inside look into a 15-year collaboration between the scientists at Lovelace Biomedical and engineers at Capsugel, a company that develops and manufactures dosage forms for the biopharmaceutical and consumer health industries.
After Capsugel created an aerosol drug formulation using spray-drying and encapsulation technologies, it was up to Lovelace to identify clinically relevant in vivo models for pharmacology, pharmacokinetic and toxicology assessment of various agents.
In this webinar, you’ll learn about:
- Evaluation of the ejection and delivery efficiency of the biological EXUBERA (insulin human) and a novel insulin formulation engineered by Capsugel, via a PK/PD canine model. (See also Kuehl, et al., AAPS PharmSciTech, 15(6), 2014.)
- A PK/PD study with an aerosol formulation of endogenous peptide YY (PYY), known to cause appetite suppression when delivered via multiple injection modalities, in a small animal model. (See also Kuehl, et al., Drug Dev Ind Pharm, 2016; 42(1); 150-156.)
- An evaluation of the differences of PK between amorphous and crystalline formulations of inhaled fluticasone and FLOVENT pMDI in a large animal model.
The presentation also includes information on process development of early-phase clinical supplies, as well as late-stage clinical/commercial strategies, including encapsulation case studies for aerosolized drugs.
Watch the Webinar: Engineered Particle Platform for Rapid Assessment of Inhaled Formulations: In Vivo Evaluations